These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 35863587)

  • 41. Regulation of G protein-coupled receptors by allosteric ligands.
    Lane JR; Abdul-Ridha A; Canals M
    ACS Chem Neurosci; 2013 Apr; 4(4):527-34. PubMed ID: 23398684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.
    Lindsley CW; Emmitte KA; Hopkins CR; Bridges TM; Gregory KJ; Niswender CM; Conn PJ
    Chem Rev; 2016 Jun; 116(11):6707-41. PubMed ID: 26882314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery.
    Wang Y; Yu Z; Xiao W; Lu S; Zhang J
    Drug Discov Today; 2021 Mar; 26(3):690-703. PubMed ID: 33301977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in G protein-coupled receptor allostery: from function to structure.
    Christopoulos A
    Mol Pharmacol; 2014 Nov; 86(5):463-78. PubMed ID: 25061106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?
    Szlenk CT; Gc JB; Natesan S
    Mol Pharmacol; 2019 Nov; 96(5):527-541. PubMed ID: 30967440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
    Bian Y; Feng Z; Yang P; Xie XQ
    AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs.
    Burggraaff L; van Veen A; Lam CC; van Vlijmen HWT; IJzerman AP; van Westen GJP
    J Chem Inf Model; 2020 Oct; 60(10):4664-4672. PubMed ID: 32931270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
    Fronik P; Gaiser BI; Sejer Pedersen D
    J Med Chem; 2017 May; 60(10):4126-4134. PubMed ID: 28140580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Binding Characterization of GPCRs-Modulator by Molecular Complex Characterizing System (MCCS).
    Feng Z; Liang T; Wang S; Chen M; Hou T; Zhao J; Chen H; Zhou Y; Xie XQ
    ACS Chem Neurosci; 2020 Oct; 11(20):3333-3345. PubMed ID: 32941011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.
    Rodríguez D; Ranganathan A; Carlsson J
    Curr Top Med Chem; 2015; 15(24):2484-503. PubMed ID: 26126906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Wandering beyond small molecules: peptides as allosteric protein modulators.
    Mannes M; Martin C; Menet C; Ballet S
    Trends Pharmacol Sci; 2022 May; 43(5):406-423. PubMed ID: 34857409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rational design of dualsteric GPCR ligands: quests and promise.
    Mohr K; Tränkle C; Kostenis E; Barocelli E; De Amici M; Holzgrabe U
    Br J Pharmacol; 2010 Mar; 159(5):997-1008. PubMed ID: 20136835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
    De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
    Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From G Protein-coupled Receptor Structure Resolution to Rational Drug Design.
    Jazayeri A; Dias JM; Marshall FH
    J Biol Chem; 2015 Aug; 290(32):19489-95. PubMed ID: 26100628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs.
    Hudson BD; Ulven T; Milligan G
    Curr Top Med Chem; 2013; 13(1):14-25. PubMed ID: 23409763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs.
    Digby GJ; Conn PJ; Lindsley CW
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):587-94. PubMed ID: 20812150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
    Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
    Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research progress of indole-fused derivatives as allosteric modulators: Opportunities for drug development.
    Luo ML; Zhao Q; He XH; Xie X; Zhu HP; You FM; Peng C; Zhan G; Huang W
    Biomed Pharmacother; 2023 Jun; 162():114574. PubMed ID: 36996677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators.
    Bennett KA; Christopher JA; Tehan BG
    Adv Pharmacol; 2020; 88():35-58. PubMed ID: 32416871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.